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isocentric rotational delivery (DIR) where the gantry moves to 
multiple positions and delivers a ray of spots with various energies 
from each fixed gantry position without lateral beam scanning. A 
cylindrical water phantom with a cylindrical target (3.3cm length, 
5cm diameter) in the middle of the phantom has been chosen. For 
3DSS also a lung tumour patient case has been evaluated. For both 
cases a dose of 60Gy was prescribed to the CTV in a single fraction. 
Spot positions and weights were derived and the dose was 
recalculated with a dose calculation algorithm. For each delivery 
method and case two plans were derived: one with the isocenter (IC) 
positioned in the middle of a CT-voxel andone with the IC shifted by 
0.4 (0.3)mm (CT grid: Δx=Δy=Δz=1mm) for the cylinder phantom 
(patient) relative to the IC in each direction simulating a small setup 
error. 
Results: Table 1 summarizes the minimal doses to 1%, 50% and 95% of 
the target. The most robust method shows to be the 3DSS. Particularly 
for the water phantom the dose differences are minor. However, this 
is not valid for the patient case. Here, even with 3DSS the minimal 
dose to 95% of the volume was reduced by almost 3Gy due to the IC 
shift. Furthermore, local dose differences up to almost 8% within the 
target and 3mm distant (cc direction) to the IC were found. Generally, 
the dose differences between the two plans are most obvious within 
the gradient region. The DET methodis less robust. The general trend 
is the same as for the 3DSS case but absolute local differences are up 
to almost 5Gy at 14mm distant from the IC slice. With this technique 
the dose differences are mainly in the gradient region of the dose 
distribution. The DIR method is most sensitive to the setup-errors, 
where the beam rotates around the IC without lateral scanning. The IC 
shift therefore shifts the dose distribution in the same direction for all 
beams. Therefore, the detrimental effects can accumulate. Dose 
differences for the two plans are up to 7% even within the IC slice. 
 
Conclusions: The results show that even very small setup errors that 
cannot be completely avoided through image guidance can influence 
the resulting dose distributions depending on the delivery method for 
proton therapy. However, the presented results assume a single 
fraction delivery which is not the usual clinical practice but illustrates 
the effect best. For fractionated treatment the effects should be 
reduced, however, based on the presented results, studies evaluating 
the residual effects with particular respect to the applied delivery 
technique are required. 
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Purpose/Objective: IMRT and VMAT for RT of pancreatic cancer can 
reduce toxicity to OARs such as stomach, small intestines and kidneys, 
but the tight conformity of the high-dose surface to the target area in 
these techniques requires highly accurate positioning. Daily cone-
beam CT (CBCT) enables pretreatment correction of patient setup 
errors. The pancreas shows considerable day-to-day positional 
variation relative to the vertebrae, which can introduce substantial 
systematic and random setup errors. The use of intratumoral fiducial 
markers, visible on CBCT, can help reduce the setup errors and 
decrease the currently large PTV. The aim of our study is to quantify 
interfractional variation in tumor position using fiducials and CBCT 
and thus determine the potential benefit of using intratumoral 
fiducials rather than bony anatomy for daily pancreatic patient setup 
verification.  
Materials and Methods: Eleven consecutive pancreatic cancer 
patients were included in our study and each received 2 to 3 gold 
fiducial markers (Visicoil; 0.35 mm diameter) by endoscopic 
ultrasound-guided implantation. The two markers of one patient could 
later not be located on the reference CT. In the other 10 patients, a 
total of 25 markers were visible on the CT as well as on all CBCTs. For 
these patients, who received 25 × 2Gy, a total of 242 CBCTs were 
registered with the reference CT on bony anatomy and on each of the 
markers. From this, the displacement of markers relative to the 
vertebrae was determined, as well as the distance between marker 
pairs. Marker migration, tissue deformation and marker localization 
error all affect the distance between two markers. To validate the use 
of the fiducial markers as indicator of tumor position, we analyzed the 
20 marker pair distances using linear fits to the CBCT data.  
Results: Pair distances showed only slight trends (mean slope of -0.03 
mm/day, range -0.10 to 0.02 mm/day, 5/20 with p<0.05), most likely 
due to tissue deformation (shrinkage), but no clear shifts that would 
indicate marker migration. The residuals of the linear fits had a mean 
SD of 0.8 mm (range 0.4–1.3 mm), a measure for localization error. 
From the positional variation, we found for these ten patients an SD 
of systematic error Σ of 4.0, 5.3 and 3.6 mm and an SD of random 
error σ of 3.6, 4.9, and 2.3 mm, in LR, SI and AP, respectively. See 
the Figure for the distributions in the SI-direction.  
 
  
For 11% (26/242) of fractions, the vector displacement relative to 
bony anatomy was >15mm; 29% (69/242) showed a vector 
displacement >10mm. For one patient the vector displacement for 
72% (18/25) of fractions was >10mm.  
Conclusions: This study of interfractional variation of pancreatic 
tumor position shows large mean displacements (systematic errors) in 
addition to a wide spread in positional range between patients. This 
strongly supports the benefit of on-line position verification based on 
the tumor itself rather than on bony anatomy, and hence the 
necessity of implantation of intratumoral fiducial markers. 
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Purpose/Objective: In the context of dose accumulation in prostate 
IGRT, most proposed methods assume that the fraction dose can be 
approximated by a propagation of the planned dose. The objectives of 
this study were to quantify the uncertainties resulting from this 
approximation.  
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Materials and Methods:  
 20 patients receiving 80Gy with prostate IGRT underwent one planning 
CT and 8 weekly CTs. The prostate, seminal vesicles (SV) and OARs 
were manually delineated by one expert on all CT datasets. An IMRT 
treatment plan was generated on each planning CT. Deformable 
registration was used in order to estimate the actually delivered dose 
during the treatment. An in-house registration method, using the 
manually delineated contours, was used in order to register weekly 
CTs to the planning CT. The resulting deformation fields were used to 
propagate the dose distributions on weekly CTs and obtain the weekly 
cumulative doses. Two methods were used to obtain the dose 
distributions on weekly CTs: They were either approximated by the 
planned dose or recalculated according to the treatment parameters. 
We quantified the differences between: (i) the recalculated dose 
distributions at each fraction and the propagated planned dose; (ii) 
the cumulated dose by using propagation of the planned dose (C1) and 
the cumulated dose by using the recalculated doses (C2); (iii) the 
planned dose distribution (P) and cumulated dose distributions(C1 and 
C2). (figure) 
Results: Small differences (mean difference <1Gy for all patients and 
all organs) were observed between the planned dose after 
propagation and the weekly recalculated dose. The maximal 
difference observed in the patient cohort was 3.7Gy, 6.1Gy, and 
8.5Gy for the prostate, bladder and rectum, respectively. The largest 
differences observed in the rectum were caused by the presence or 
absence of gas. The mean Dice scores after registration were 
0.93±0.01, 0.85±0.05, 0.95±0.02, and 0.93±0.02 for the prostate, SV, 
bladder, and rectum, respectively. Considering the two cumulated 
doses C1 and C2, the mean differences between mean doses (Gy) 
within the prostate, SV, bladder and rectum wall were 0.14±0.45, 
0.10±0.40, 0.11±0.34, and 0.08±0.22, respectively. The point-by-point 
absolute dose differences were less than 2.1Gy, 3.1Gy, and 3.9Gy for 
the prostate, bladder, and rectum, respectively. Considering the 
difference between C1 and the planned dose P, the mean differences 
between the mean doses (Gy) within the prostate, SV, bladder wall 
and rectum wall were -0.07±0.13, -0.35±1.50, 0.44±7.91, and -
0.98±2.03, respectively. The absolute difference reached 15.6Gy for 
the bladder wall and 6.3Gyfor the rectum wall. Similar differences 
were observed when considering C2. 
Conclusions: For prostate IGRT, approximating the dose distribution 
at each fraction by the planned dose distribution has a low impact on 
cumulated dose estimation. Conversely, the cumulated dose in the 
rectum and bladder can be dramatically higher than the planned dose. 
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Purpose/Objective: Delineation of CTVs on a planning CT (pCT) by 
clinicians for head and neck cancer is time consuming (>2hrs/patient). 
When patients change shape during treatment (i.e. weight loss) then 
CTVs must be re-delineated on a replan CT (rCT). Deformable image 
registration software can register pCT to rCT to allow transfer of pCT 
volumes to rCT. The aim of this work was to 1) assess the accuracy of 
segmenting CTVs on rCT using atlas based automatic segmentation 
(ABAS) and compare accuracy with inter- and intra-observer variability 
2) estimate time savings.  
Materials and Methods: Fifteen patients (pt) with both pCT and rCT 
were selected. One clinician (clin) delineated high dose (HD) and low 
dose (LD) CTVs on pCT and up to 3 clin on 3 occasions delineated CTVs 
on rCT. CTVs, delineated on pCT manually, were used as an atlas for 
ABAS to segment volumes on rCT. Finally, one clin edited ABAS CTVs 
so they were clinically acceptable. A flowchart of volumes produced is 
shown in figure 1. Steps 2 and 6 were timed to estimate time savings 
using ABAS. CTVs were compared using mean distance to agreement 
(MDA), dice similarity coefficient (DSC) and normalised dice 
coefficient (nDSC). nDSC is DSC divided by an uncertainty index, the 
DSC between the manual volume and the manual volume reduced 
uniformly by a set distance. This distance was set as the mean inter-
observer MDA (2mm). nDSC is an important parameter as, unlike DSC, 
it does not have a volume size dependence. nDSC> 1 indicates volumes 
agree within an uncertainty of 2mm. Figure 1. Flow chart of the 
manually delineated and ABAS segmented contours on both the pCT 
and rCT as well as the aims of the analysis from each step. 
  
  
Results: Volume comparison results for both CTVHD and CTVLD are 
shown in table 1. Inter-observer variability was higher than intra-
observer variability but both led to MDA < 2.3mm. The inter- and 
intra-observer variability of delineating CTVHD was lower for CTVLD as 
CTVHD generally contained more, well-defined, boundaries, whereas, 
particularly the inferior aspects of CTVLD, were less well defined by 
anatomical boundaries. ABAS contours were found to agree with 
manual delineations to within inter-observer variability when both 
MDA and nDSC were considered. However some minor editing was 
required. The mean(1SD) times taken by a clinician to both delineate 
and edit ABAS CTVs were 169min (25min) and 57min (11min) 
respectively.  
Table 1. Results showing the mean volume comparison results (MDA, 
DSC and nDSC) for inter- and intra-observer variability as well as 
comparing manual volumes against both ABAS segmented volumes and 
edited ABAS segmented volumes. 
 
 
Conclusions: Inter-observer variability in CTV delineation was higher 
than intra-observer variability and ABAS volumes were mostly within 
inter-observer variability. This analysis did not identify small local 
differences in contours of clinical importance, for which ABAS volumes 
required minor editing. A time saving of approximately 67% was 
achieved by editing ABAS produced CTV volumes compared to full 
manual delineation. 
   
 
